Jefferies Group reiterated their buy rating on shares of Zoetis (NYSE:ZTS) in a report released on Friday, November 10th. Jefferies Group also issued estimates for Zoetis’ FY2017 earnings at $2.39 EPS, FY2018 earnings at $2.79 EPS, FY2019 earnings at $3.21 EPS, FY2020 earnings at $3.63 EPS and FY2021 earnings at $4.00 EPS.
Several other research analysts have also recently commented on the company. Deutsche Bank reaffirmed a buy rating and issued a $65.00 target price (up from $62.00) on shares of Zoetis in a research report on Monday, July 17th. Zacks Investment Research cut Zoetis from a buy rating to a hold rating in a research report on Wednesday, November 1st. Stifel Nicolaus reaffirmed a buy rating and issued a $65.00 target price on shares of Zoetis in a research report on Friday, September 1st. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the stock a buy rating in a research report on Monday, August 14th. Finally, BidaskClub raised Zoetis from a sell rating to a hold rating in a research report on Friday, October 13th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. Zoetis currently has a consensus rating of Buy and a consensus target price of $68.24.
Zoetis (ZTS) traded up $0.22 on Friday, hitting $71.61. The stock had a trading volume of 1,618,600 shares, compared to its average volume of 2,781,101. The company has a market capitalization of $34,790.00, a PE ratio of 32.70, a price-to-earnings-growth ratio of 2.10 and a beta of 1.02. Zoetis has a 12 month low of $48.55 and a 12 month high of $72.14. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be issued a dividend of $0.105 per share. The ex-dividend date is Wednesday, November 8th. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.59%. Zoetis’s payout ratio is presently 22.11%.
Hedge funds and other institutional investors have recently modified their holdings of the business. Dynamic Technology Lab Private Ltd increased its stake in shares of Zoetis by 7.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after buying an additional 401 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Zoetis by 8.2% in the second quarter. Wells Fargo & Company MN now owns 5,113,948 shares of the company’s stock valued at $319,008,000 after buying an additional 389,260 shares in the last quarter. Swiss National Bank increased its stake in shares of Zoetis by 8.1% in the second quarter. Swiss National Bank now owns 1,796,380 shares of the company’s stock valued at $112,058,000 after buying an additional 133,900 shares in the last quarter. Balyasny Asset Management LLC increased its stake in shares of Zoetis by 55.5% in the second quarter. Balyasny Asset Management LLC now owns 44,330 shares of the company’s stock valued at $2,765,000 after buying an additional 15,830 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Zoetis by 13.9% in the second quarter. Victory Capital Management Inc. now owns 277,641 shares of the company’s stock valued at $17,320,000 after buying an additional 33,894 shares in the last quarter. 93.33% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Zoetis’ (ZTS) “Buy” Rating Reaffirmed at Jefferies Group” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://baseballnewssource.com/markets/zoetis-zts-buy-rating-reaffirmed-at-jefferies-group-llc/1774292.html.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with our FREE daily email newsletter.